Skip to main content
OpenTrials
Completed

NCT Number: NCT01121653

Impact of Oral Magnesium on Neuropathic Pain

Use lay language.

The aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Patient With Neuropathic Pain Nervous System Diseases Neuralgia Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

About this study

Protocol description

Visit D0

  • patient inclusion after informed signed consent
  • clinical exam
  • blood sampling (magnesium dosage)
  • questionnaires (neuropathic pain and quality of life)
  • daily self-evaluation on neuropathic pain scale (Week0 to Week5)

D8 : first intake of study drug (magnesium or placebo)

Visit Week5:

  • questionnaires (neuropathic pain and quality of life)
  • blood sampling (magnesium dosage)
  • clinical exam

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • neuropathic pain
  • informed signed consent

Exclusion criteria

  • magnesium intake contra-indication
  • severe renal insufficiency
  • quinidine intake
  • concomitant treatment change 2weeks before inclusion
  • evolutive pathology

Treatment and study plan

Magnogene ® (magnesium)

Drug

evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.

Primary outcomes

  1. Pain scores (neuropathic pain evaluation questionnaire)

    Time frame: Visit D0

Secondary outcomes

  1. - Numeric scale - quality o f life questionnaires

    Time frame: Visit Week 5

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
May 12, 2010
Registry last updated
May 12, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.